aTyr Pharma (LIFE) Stock Forecast, Price Target & Predictions
LIFE Stock Forecast
aTyr Pharma stock forecast is as follows: an average price target of $11.00 (represents a 623.68% upside from LIFE’s last price of $1.52) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
LIFE Price Target
The average price target for aTyr Pharma (LIFE) is $11.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 623.68% upside from LIFE's last price of $1.52.
LIFE Analyst Ratings
According to 1 Wall Street analysts, aTyr Pharma's rating consensus is 'Buy'. The analyst rating breakdown for LIFE stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
aTyr Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 18, 2022 | - | Piper Sandler | $11.00 | $3.20 | 243.75% | 623.68% |
The latest aTyr Pharma stock forecast, released on May 18, 2022 by Piper Sandler company, set a price target of $11.00, which represents a 243.75% increase from the stock price at the time of the forecast ($3.20), and a 623.68% increase from LIFE last price ($1.52).
aTyr Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $1.52 | $1.52 | $1.52 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of aTyr Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to aTyr Pharma's last price of $1.52. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 05, 2023 | Oppenheimer | - | Perform | Downgrade |
| Aug 15, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| May 18, 2022 | Piper Sandler | Overweight | Overweight | Hold |
aTyr Pharma's last stock rating was published by Piper Sandler on Aug 14, 2024. The company gave LIFE a "Overweight" rating, the same as its previous rate.
aTyr Pharma Financial Forecast
aTyr Pharma Revenue Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.39M | - | - | - | - | - | - | - | $2.05M | - | - | $8.06M | $144.00K | - |
| Avg Forecast | $144.87K | $155.24K | $166.34K | $178.25K | $5.00K | $32.50K | $30.00K | $36.67K | $3.42M | $1.50M | $611.67K | $2.36M | $357.14K | $400.00K | $2.50M | $200.00K | $2.52M | $266.67K | $621.80K | $3.98M | $126.00K | $103.33K | $399.10K | $4.40M | $155.77K | $60.00K |
| High Forecast | $144.87K | $155.24K | $166.34K | $178.25K | $5.00K | $32.50K | $30.00K | $36.67K | $3.42M | $1.50M | $611.67K | $2.36M | $357.14K | $400.00K | $2.50M | $200.00K | $2.52M | $266.67K | $621.80K | $3.98M | $126.00K | $103.33K | $399.10K | $4.40M | $155.77K | $60.00K |
| Low Forecast | $144.87K | $155.24K | $166.34K | $178.25K | $5.00K | $32.50K | $30.00K | $36.67K | $3.42M | $1.50M | $611.67K | $2.36M | $357.14K | $400.00K | $2.50M | $200.00K | $2.52M | $266.67K | $621.80K | $3.98M | $126.00K | $103.33K | $399.10K | $4.40M | $155.77K | $60.00K |
| # Analysts | - | - | - | - | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 29.08% | - | - | - | - | - | - | - | 16.29% | - | - | 1.83% | 0.92% | - |
aTyr Pharma's average Quarter revenue forecast for Mar 23 based on 1 analysts is $2.36M, with a low forecast of $2.36M, and a high forecast of $2.36M. LIFE's average Quarter revenue forecast represents a -77.24% decrease compared to the company's last Quarter revenue of $10.39M (Dec 22).
aTyr Pharma EBITDA Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-12.03M | $-7.95M | - | - | $-12.08M | $-8.24M | - | - | $-6.85M | $-4.69M | - | - | $2.11M | $-5.62M | - |
| Avg Forecast | $-86.92K | $-93.14K | $-99.81K | $-106.95K | $-3.00K | $-19.50K | $-18.00K | $-22.00K | $-2.05M | $-900.00K | $-367.00K | $-1.42M | $-214.28K | $-240.00K | $-1.50M | $-8.05M | $-1.51M | $-160.00K | $-373.08K | $-3.09M | $-75.60K | $-62.00K | $-239.46K | $-2.64M | $-93.46K | $-36.00K |
| High Forecast | $-86.92K | $-93.14K | $-99.81K | $-106.95K | $-3.00K | $-19.50K | $-18.00K | $-22.00K | $-2.05M | $-900.00K | $-367.00K | $-1.42M | $-214.28K | $-240.00K | $-1.50M | $-6.44M | $-1.51M | $-160.00K | $-373.08K | $-2.47M | $-75.60K | $-62.00K | $-239.46K | $-2.64M | $-93.46K | $-36.00K |
| Low Forecast | $-86.92K | $-93.14K | $-99.81K | $-106.95K | $-3.00K | $-19.50K | $-18.00K | $-22.00K | $-2.05M | $-900.00K | $-367.00K | $-1.42M | $-214.28K | $-240.00K | $-1.50M | $-9.66M | $-1.51M | $-160.00K | $-373.08K | $-3.70M | $-75.60K | $-62.00K | $-239.46K | $-2.64M | $-93.46K | $-36.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 8.48% | 37.10% | - | - | 1.50% | 5.46% | - | - | 2.22% | 61.98% | - | - | -0.80% | 60.14% | - |
1 analysts predict LIFE's average Quarter EBITDA for Jul 20 to be $-239.46K, with a high of $-239.46K and a low of $-239.46K. This is -111.34% lower than aTyr Pharma's previous annual EBITDA (Mar 20) of $2.11M.
aTyr Pharma Net Income Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-11.12M | $-7.09M | - | - | $-11.93M | $-8.56M | - | - | $-7.15M | $-4.93M | - | - | $1.75M | $-5.97M | - |
| Avg Forecast | $-5.29M | $-6.61M | $-10.57M | $-10.57M | $-14.93M | $-15.73M | $-15.73M | $-16.52M | $-15.73M | $-14.93M | $-18.41M | $-23.13M | $-31.72M | $-30.62M | $-25.24M | $-8.10M | $-18.72M | $-39.18M | $-33.57M | $-3.20M | $-54.41M | $-49.12M | $-48.24M | $5.35M | $-105.07M | $-114.10M |
| High Forecast | $-5.29M | $-6.61M | $-10.57M | $-10.57M | $-14.93M | $-15.73M | $-13.58M | $-16.52M | $-13.91M | $-14.93M | $-18.41M | $-23.13M | $-31.72M | $-30.62M | $-25.24M | $-6.48M | $-18.72M | $-39.18M | $-33.57M | $-2.56M | $-54.41M | $-49.12M | $-48.24M | $6.42M | $-105.07M | $-114.10M |
| Low Forecast | $-5.29M | $-6.61M | $-10.57M | $-10.57M | $-14.93M | $-15.73M | $-17.87M | $-16.52M | $-16.94M | $-14.93M | $-18.41M | $-23.13M | $-31.72M | $-30.62M | $-25.24M | $-9.72M | $-18.72M | $-39.18M | $-33.57M | $-3.83M | $-54.41M | $-49.12M | $-48.24M | $4.28M | $-105.07M | $-114.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.48% | 0.22% | - | - | 1.47% | 0.46% | - | - | 2.24% | 0.09% | - | - | 0.33% | 0.06% | - |
aTyr Pharma's average Quarter net income forecast for Jul 20 is $-48.24M, with a range of $-48.24M to $-48.24M. LIFE's average Quarter net income forecast represents a -2851.79% decrease compared to the company's last Quarter net income of $1.75M (Mar 20).
aTyr Pharma SG&A Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $3.41M | $3.43M | - | - | $3.48M | $2.69M | - | - | $2.69M | $2.29M | - | - | $2.59M | $2.52M | - |
| Avg Forecast | $1.58M | $1.69M | $1.81M | $1.94M | $54.38K | $353.46K | $326.27K | $398.78K | $37.19M | $16.31M | $6.65M | $25.71M | $3.88M | $4.35M | $27.19M | $2.18M | $27.37M | $2.90M | $6.76M | $1.20M | $1.37M | $1.12M | $4.34M | $47.84M | $1.69M | $652.54K |
| High Forecast | $1.58M | $1.69M | $1.81M | $1.94M | $54.38K | $353.46K | $326.27K | $398.78K | $37.19M | $16.31M | $6.65M | $25.71M | $3.88M | $4.35M | $27.19M | $2.18M | $27.37M | $2.90M | $6.76M | $1.44M | $1.37M | $1.12M | $4.34M | $47.84M | $1.69M | $652.54K |
| Low Forecast | $1.58M | $1.69M | $1.81M | $1.94M | $54.38K | $353.46K | $326.27K | $398.78K | $37.19M | $16.31M | $6.65M | $25.71M | $3.88M | $4.35M | $27.19M | $2.18M | $27.37M | $2.90M | $6.76M | $960.25K | $1.37M | $1.12M | $4.34M | $47.84M | $1.69M | $652.54K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.13% | 0.88% | - | - | 1.60% | 0.10% | - | - | 2.24% | 1.67% | - | - | 0.05% | 1.49% | - |
aTyr Pharma's average Quarter SG&A projection for Jul 23 is $6.65M, based on 1 Wall Street analysts, with a range of $6.65M to $6.65M. The forecast indicates a 95.20% rise compared to LIFE last annual SG&A of $3.41M (Mar 23).
aTyr Pharma EPS Forecast
| Dec 25 | Oct 25 | Jul 25 | Mar 25 | Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | Mar 22 | Dec 21 | Oct 21 | Jul 21 | Mar 21 | Dec 20 | Oct 20 | Jul 20 | Mar 20 | Dec 19 | Oct 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 3 | 2 | 3 | 1 | 1 | 1 | - | - | - | - | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.27 | $-0.24 | - | - | $-0.43 | $-0.31 | - | - | $-0.51 | $-0.47 | - | - | $0.25 | $-1.54 | - |
| Avg Forecast | $-0.08 | $-0.10 | $-0.16 | $-0.16 | $-0.23 | $-0.24 | $-0.24 | $-0.25 | $-0.24 | $-0.23 | $-0.28 | $-0.35 | $-0.48 | $-0.46 | $-0.38 | $-0.32 | $-0.28 | $-0.59 | $-0.51 | $-0.32 | $-0.82 | $-0.74 | $-0.73 | $-0.18 | $-1.59 | $-1.73 |
| High Forecast | $-0.08 | $-0.10 | $-0.16 | $-0.16 | $-0.23 | $-0.24 | $-0.21 | $-0.25 | $-0.21 | $-0.23 | $-0.28 | $-0.35 | $-0.48 | $-0.46 | $-0.38 | $-0.32 | $-0.28 | $-0.59 | $-0.51 | $-0.32 | $-0.82 | $-0.74 | $-0.73 | $-0.18 | $-1.59 | $-1.73 |
| Low Forecast | $-0.08 | $-0.10 | $-0.16 | $-0.16 | $-0.23 | $-0.24 | $-0.27 | $-0.25 | $-0.26 | $-0.23 | $-0.28 | $-0.35 | $-0.48 | $-0.46 | $-0.38 | $-0.32 | $-0.28 | $-0.59 | $-0.51 | $-0.32 | $-0.82 | $-0.74 | $-0.73 | $-0.18 | $-1.59 | $-1.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.77% | 0.50% | - | - | 1.36% | 1.09% | - | - | 1.61% | 0.57% | - | - | -1.39% | 0.97% | - |
According to 1 Wall Street analysts, aTyr Pharma's projected average Quarter EPS for Jul 20 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -392.00% decrease compared to LIFE previous annual EPS of $0.25 (Mar 20).
aTyr Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
LIFE Forecast FAQ
Is aTyr Pharma a good buy?
Yes, according to 1 Wall Street analysts, aTyr Pharma (LIFE) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of LIFE's total ratings.
What is LIFE's price target?
aTyr Pharma (LIFE) average price target is $11 with a range of $11 to $11, implying a 623.68% from its last price of $1.52. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will aTyr Pharma stock go up soon?
According to Wall Street analysts' prediction for LIFE stock, the company can go up by 623.68% (from the last price of $1.52 to the average price target of $11), up by 623.68% based on the highest stock price target, and up by 623.68% based on the lowest stock price target.
Can aTyr Pharma stock reach $2?
LIFE's average twelve months analyst stock price target of $11 supports the claim that aTyr Pharma can reach $2 in the near future.
What are aTyr Pharma's analysts' financial forecasts?
aTyr Pharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $104.17K (high $104.17K, low $104.17K), average EBITDA is $-62.5K (high $-62.5K, low $-62.5K), average net income is $-62.909M (high $-60.764M, low $-65.053M), average SG&A $1.13M (high $1.13M, low $1.13M), and average EPS is $-0.952 (high $-0.92, low $-0.984). LIFE's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $644.7K (high $644.7K, low $644.7K), average EBITDA is $-387K (high $-387K, low $-387K), average net income is $-33.04M (high $-33.04M, low $-33.04M), average SG&A $7.01M (high $7.01M, low $7.01M), and average EPS is $-0.5 (high $-0.5, low $-0.5).
Did the LIFE's actual financial results beat the analysts' financial forecasts?
Based on aTyr Pharma's last annual report (Dec 2023), the company's revenue was $353K, which missed the average analysts forecast of $7.9M by -95.53%. Apple's EBITDA was $-54.919M, beating the average prediction of $-4.737M by 1059.26%. The company's net income was $-50.389M, missing the average estimation of $-72.198M by -30.21%. Apple's SG&A was $12.98M, missing the average forecast of $85.87M by -84.89%. Lastly, the company's EPS was $-94, beating the average prediction of $-1.093 by 8503.57%. In terms of the last quarterly report (Dec 2022), aTyr Pharma's revenue was $10.39M, beating the average analysts' forecast of $357.14K by 2808.08%. The company's EBITDA was $-7.95M, beating the average prediction of $-214K by 3610.01%. aTyr Pharma's net income was $-7.094M, missing the average estimation of $-31.719M by -77.63%. The company's SG&A was $3.43M, missing the average forecast of $3.88M by -11.80%. Lastly, the company's EPS was $-0.24, missing the average prediction of $-0.48 by -50.00%